Clinical evaluation of a soluble trimeric HIV-1 envelope glycoprotein vaccine

A Trimeric, V2-Deleted HIV-1 Envelope Glycoprotein Vaccine Elicits Potent Neutralizing Antibodies but Limited Breadth of Neutralization in Human Volunteers

(2011) Paul Spearman et al.   JOURNAL OF INFECTIOUS DISEASES

Magnitude and Breadth of a Nonprotective Neutralizing Antibody Response in an Efficacy Trial of a Candidate HIV‐1 gp120 Vaccine

(2010) Peter Gilbert et al.   JOURNAL OF INFECTIOUS DISEASES

First phase I clinical trial of an HIV-1 subtype D gp140 envelope protein vaccine: immune activity induced in all study participants

(2009) Julia L Hurwitz et al.   AIDS

Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand

(2009) Supachai Rerks-Ngarm et al.   NEW ENGLAND JOURNAL OF MEDICINE

Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1

(2009) Yun (Kenneth) Kang et al.   VACCINE

Biochemical and biophysical comparison of cleaved and uncleaved soluble, trimeric HIV-1 envelope glycoproteins

(2009) Antu K. Dey et al.   VIROLOGY

Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge

(2008) Willy M.J.M. Bogers et al.   VIROLOGY